| Ofir Wolaj, MD | |
|
450 Brookline Ave, Dana 2058, Boston, MA 02215-5418 | |
| (617) 632-6139 | |
| Not Available |
| Full Name | Ofir Wolaj |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 450 Brookline Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013334580 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 258018 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ofir Wolaj, MD 450 Brookline Ave, Dana 2058, Boston, MA 02215-5418 Ph: () - | Ofir Wolaj, MD 450 Brookline Ave, Dana 2058, Boston, MA 02215-5418 Ph: (617) 632-6139 |
News Archive
Britain's first swine flu vaccine trials, led by the University of Leicester and University Hospitals of Leicester NHS Trust, are taking place at the Leicester Royal Infirmary.
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of Pittsburgh Cancer Institute, Yale Cancer Center and City of Hope in Los Angeles, which participated in study enrollment, and the University of Southern California and University College Cork in Ireland, which collaborated on analysis of the data.
Breast cancer is the most common cancer in women worldwide and the second most common cancer overall. Although it can now be treated with drugs, many of these drugs mysteriously stop working after some time, causing a relapse.
New findings show that eating a high-fat diet beginning at puberty speeds up the development of breast cancer and may actually increase the risk of cancer similar to a type often found in younger adult women.
Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte (inventors of the upcyte® technology) and Reinnervate (market leaders in the growing field of 3D cell culture) said they will work together to combine their upcyte® and Alvetex®Scaffold technologies to bring next generation cell bases assays to the biopharma and academic research markets.
› Verified 4 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |